{"entity":{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","aka":[],"tldr":"Leading nasopharyngeal carcinoma researcher who directs the Hong Kong Cancer Institute at CUHK.","summary":"Anthony Chan is Li Shu Fan Medical Foundation Professor of Clinical Oncology at The Chinese University of Hong Kong, Director of the Hong Kong Cancer Institute and a Pro-Vice-Chancellor of the university. His research has shaped the treatment of nasopharyngeal carcinoma, including trials of concurrent chemoradiotherapy and studies of plasma Epstein-Barr virus DNA as a biomarker.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+AT%5BAuthor%5D+nasopharyngeal"}],"tags":["leadership","clinician-scientist","nasopharyngeal cancer","head and neck cancer"],"related":[],"cancers":["nasopharyngeal","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["prince-of-wales-hospital-cuhk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Li Shu Fan Medical Foundation Professor of Clinical Oncology; Director, Hong Kong Cancer Institute","institutionId":"prince-of-wales-hospital-cuhk","specialisms":["Nasopharyngeal carcinoma","Head and neck cancer","EBV-related cancers"],"profiles":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+AT%5BAuthor%5D+nasopharyngeal"}],"papers":[{"title":"Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial","journal":"Journal of Clinical Oncology","year":2002,"doi":"10.1200/jco.2002.08.149"},{"title":"Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA","journal":"Journal of Clinical Oncology","year":2004,"doi":"10.1200/jco.2004.05.178"},{"title":"A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mdr401"}]},"route":"/people/anthony-chan/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"}],"institution":[{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/"}]}}